全文获取类型
收费全文 | 38460篇 |
免费 | 1950篇 |
国内免费 | 402篇 |
专业分类
耳鼻咽喉 | 455篇 |
儿科学 | 786篇 |
妇产科学 | 1012篇 |
基础医学 | 4444篇 |
口腔科学 | 1127篇 |
临床医学 | 2897篇 |
内科学 | 10129篇 |
皮肤病学 | 599篇 |
神经病学 | 4277篇 |
特种医学 | 1478篇 |
外科学 | 6090篇 |
综合类 | 81篇 |
一般理论 | 6篇 |
预防医学 | 1495篇 |
眼科学 | 535篇 |
药学 | 2200篇 |
中国医学 | 64篇 |
肿瘤学 | 3137篇 |
出版年
2024年 | 32篇 |
2023年 | 357篇 |
2022年 | 798篇 |
2021年 | 1336篇 |
2020年 | 808篇 |
2019年 | 1034篇 |
2018年 | 1242篇 |
2017年 | 965篇 |
2016年 | 1109篇 |
2015年 | 1232篇 |
2014年 | 1601篇 |
2013年 | 2023篇 |
2012年 | 3070篇 |
2011年 | 3166篇 |
2010年 | 1725篇 |
2009年 | 1669篇 |
2008年 | 2607篇 |
2007年 | 2589篇 |
2006年 | 2323篇 |
2005年 | 2227篇 |
2004年 | 2150篇 |
2003年 | 1835篇 |
2002年 | 1656篇 |
2001年 | 239篇 |
2000年 | 165篇 |
1999年 | 244篇 |
1998年 | 305篇 |
1997年 | 271篇 |
1996年 | 248篇 |
1995年 | 198篇 |
1994年 | 154篇 |
1993年 | 143篇 |
1992年 | 130篇 |
1991年 | 97篇 |
1990年 | 106篇 |
1989年 | 115篇 |
1988年 | 75篇 |
1987年 | 81篇 |
1986年 | 80篇 |
1985年 | 52篇 |
1984年 | 80篇 |
1983年 | 72篇 |
1982年 | 58篇 |
1981年 | 57篇 |
1980年 | 52篇 |
1979年 | 26篇 |
1978年 | 24篇 |
1977年 | 23篇 |
1976年 | 19篇 |
1974年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
5.
Is it possible to make a diagnosis of raw,heated, and baked egg allergy in children using cutoffs? A systematic review 下载免费PDF全文
6.
Chiara Tanzi Gaia Fallani Francesco Magnani Giovanni Marozza Silvia Pizzarotti Bruno Zoppi Davide Lazzeroni Lorenzo Brambilla Paolo Coruzzi Luca Moderato 《La Medicina del lavoro》2020,111(2):107
Background:Cardiovascular diseases (CVD), particularly the ischemic heart disease, are a growing public health issue. In addition, the return to work after an acute cardiovascular attack represents a complex challenge.Objectives:To evaluate utility and safety of cardiopulmonary exercise testing (CPET), particularly performed “on site”, to promote a return to work in line with the residual working capacity.Methods:Fifty-nine workers affected by a major cardiovascular event, aged 18-63 years, have been enrolled between 2015 and 2018. All the patients underwent a CPET in outpatient clinic. Eleven workers also underwent the “on site” CPET, recorded during their working activities.Results:Outpatient clinic CPET outcomes (i.e. normal, mild impairment or moderate/severe impairment of cardiopulmonary function) were associated with the subjective perception of workers’ health status after returning to work. The “on site” CPET was found to be safe and reliable to promote a personalized return to work of patients. In 7 out of 11 patients, the values of O2 consumption (VO2) during the working activity were higher than 40% of VO2 max as obtained from laboratory CPET.Conclusions:This study provides evidence for safety and usefulness of “on site” CPET for a personalized statement of fitness for work. This may facilitate the job retention of patients characterized by a high risk of unnecessary job loss. The use of CPET represents a first step of energy expenditure evaluation associated with specific working tasks.Key words: Acute coronary syndrome, cardiopulmonary exercise testing, return to work 相似文献
7.
Maria Stella Aniello Davide Martino Gianluca Masi Paolo Livrea Giovanni Defazio 《Movement disorders》2006,21(4):571-575
We developed a self-administered questionnaire for screening the most common adult-onset dystonias. It was tested in 90 first-degree relatives of 22 adult-onset dystonia patients, yielding 79% sensitivity and 94% specificity. Simulation of a case-finding procedure based on serial application of the questionnaire and clinical examination of both subjects screening positive and subjects screening negative who had < 8 years of schooling increased sensitivity to 95% and specificity to 100%. This questionnaire may be an important screening resource for familial aggregation studies to be used in the context of a complex case-finding procedure. 相似文献
8.
Magdalena Cortes Alessandro Lambiase Marta Sacchetti Silvia Aronni Stefano Bonini 陈旭 《美国医学会眼科杂志(中文版)》2006,18(1):30-32
泪管-耳-牙-指(趾)(LADD)综合征是一种具有多种表现的常染色体显性遗传疾病。最初在1967年由Levy报道。1例双侧泪液系统缺失、杯状耳、干嘴,以及牙、手臂和指(趾)异常的单发病例。之后一些新发现的临床表现,如肾脏异常、唾液腺缺乏、先天性髋脱位、先天性裂孔疝和横膈疝、感觉性耳聋和传导性耳聋、牙发育不全、四肢异常、口腔干燥和眼干都被报道与此综合征有关。 相似文献
9.
10.
Adriana B Campaner Alessandro Scapinelli Ruy O Machado Roberto E Dos Santos Geni W Beznos Tsutomu Aoki 《Gynecological endocrinology》2006,22(7):395-398
We report a case of a prepubertal girl with juvenile primary hypothyroidism presenting as ovarian cysts and precocious puberty. The 7-year-old female was referred to our clinic because of a pelvic/abdominal mass and vaginal bleeding. Besides these findings, on physical examination we noticed the thyroid gland globally increased and the presence of secondary sexual characteristics. Based upon the clinical profile and investigations, the patient was diagnosed with juvenile primary hypothyroidism due to autoimmune thyroiditis. The cysts and precocious puberty resolved spontaneously after the simple replacement of thyroid hormone. It is important to bear in mind hypothyroidism in cases of girls presenting ovarian cysts and precocious puberty in order to avoid unnecessary surgery on the ovaries. 相似文献